Merck announced today that the U.S. Food and Drug Administration (FDA) has approved CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine).
CAPVAXIVE (V116) is specifically designed to help protect adults against the serotypes that cause most invasive pneumococcal disease (IPD) cases. CAPVAXIVE includes eight unique serotypes not covered by other currently approved pneumococcal vaccines.
21 Serotype Pneumococcal Vaccine Approved for Adults
Marked Increase in Pediatric RSV Hospitalizations Seen Postpandemic
Additionally, there have been higher advanced respiratory support needs in older children with fewer comorbidities than prepandemic